Create your page here
Latest News for: mcrc
Edit
MCRC Leadership gets 'back to basics' for FY22 (US Marines Corps)
Public Technologies 26 Oct 2021
Bohm, Commanding General, MCRC ... Black, joined MCRC leadership in presenting the superior achiever awards ... Bohm, MCRC Commanding General ... The training theme was 'getting back to the basics' and Marines from MCRC's National Training Team focused on helping commanders achieve sustained mission success.
Edit
MCRC briefly celebrates FY21 mission success, focuses on FY22 challenges (US Marines Corps)
Public Technologies 18 Oct 2021
) QUANTICO, Va. --. Marine Corps Recruiting Command successfully closed out Fiscal Year 2021 mission in all categories, Sept ... Gen. Jason Q. Bohm, MCRC, Commanding General ... Gen ... Bohm, MCRC Commanding General ... Cook, the Assistant Chief of Staff of Operations, MCRC ... Jeremiah Bentz, Marketing Chief and Career Recruiter, MCRC ... Maj ... Moreno, the MCRC Sergeant Major.
Edit
The Daily Times
08 Jul 2021
Cloudmed Acquires MCRC Group, Expanding Revenue Intelligence Capabilities
The Daily Times
08 Jul 2021
Edit
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
PR Newswire 12 Apr 2021
Edit
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC (Cardiff Oncology Inc)
Public Technologies 12 Apr 2021
This represents an increase over the mPFS observed in a systematic literature-based analysis of second line mCRC clinical trial data from 23 randomized trials including a total of ~10,800 patients (mPFS of ... "Notably, the ORR and mPFS observed in the trial compare very favorably to what has been seen historically in second line mCRC patients.
Edit
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC (Cardiff Oncology Inc)
Public Technologies 11 Apr 2021
care treatment and uses the same combination regimen (onvansertib 15 mg/m2 + FOLFIRI/bevacizumab) and dosing schedule as the Company's ongoing Phase 1b/2 mCRC clinical trial ... About the EAP for Onvansertib in KRAS-mutated mCRC ... The Cardiff Oncology EAP in KRAS-mutated mCRC is using the same combination treatment regimen (onvansertib 15.
Edit
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
PR Newswire 10 Apr 2021
Cardiff Oncology's EAP has enrolled participants who failed or progressed on multiple lines of standard-of-care treatment and uses the same combination regimen (onvansertib 15 mg/m2 + FOLFIRI/bevacizumab) and dosing schedule as the Company's ongoing Phase 1b/2 mCRC clinical trial ... About the EAP for Onvansertib in KRAS-mutated mCRC.
Edit
Servier veröffentlicht aktualisierte Daten zum Gesamtüberleben aus der explorativen Phase-II-Studie TASCO1 zu LONSURF® plus Bevacizumab als Erstlinienbehandlung von Patienten mit inoperablem metastasierendem Darmkrebs (mCRC), bei denen eine...
Pharmiweb 19 Jan 2021
Servier veröffentlicht aktualisierte Daten zum Gesamtüberleben aus der explorativen Phase-II-Studie TASCO1 zu LONSURF® plus Bevacizumab als Erstlinienbehandlung von Patienten mit inoperablem metastasierendem Darmkrebs (mCRC), bei denen eine Intensivtherapie nicht in Betracht kommt ... Über metastasierten Darmkrebs (mCRC).
Edit
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ...
MENA FN 18 Jan 2021
Edit
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium (Celyad SA)
Public Technologies 18 Jan 2021
'At ASCO-GI, we highlighted the encouraging median progression free-survival data from alloSHRINK which complements the previously reported tolerability, objective response rate for CYAD-101 in patients with mCRC ... Background A total of 15 patients with relapsed/refractory mCRC who ...
Edit
Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy
Pharmiweb 16 Jan 2021
Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates ... “We are very pleased with the updated results from the phase II TASCO1 study and we are continuing with our research into this promising combination in multiple mCRC settings.
Edit
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
PR Newswire 15 Jan 2021
Enrollment of patients in the Phase 1b segment of the Phase 1b/2 KRAS-mutated mCRC trial is complete and the recommended Phase 2 dose (RP2D) of onvansertib has been confirmed at 15 mg/m2 ... "This highlights the promise of onvansertib plus standard-of-care as an effective second-line treatment for patients with KRAS-mutated mCRC.
Edit
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program (Cardiff Oncology Inc)
Public Technologies 15 Jan 2021
Enrollment of patients in the Phase 1b segment of the Phase 1b/2 KRAS-mutated mCRC trial is complete and the ... "This highlights the promise of onvansertib plus standard-of-care as an effective second-line treatment for patients with KRAS-mutated mCRC ... About the Phase 1b/2 Trial of Onvansertib in KRAS-mutated mCRC.
Edit
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC (Celyad SA)
Public Technologies 15 Dec 2020
Anne Flament, Director of Clinical Development at Celyad Oncology, commented, 'The expansion cohort in our ongoing alloSHRINK trial will provide valuable data on the effectiveness of the highest dose level of CYAD-101 following preconditioning therapy in mCRC patients.
Edit
Caris Life Sciences Publishes New Data in Clinical Cancer Research Demonstrating 71% Difference in Overall Survival for mCRC Patients Using Its AI-Based MI FOLFOXai Predictor
PR Newswire 08 Dec 2020
FOLFOXai is the first clinically validated machine-learning powered molecular predictor of chemotherapy efficacy in patients with mCRC ... In addition to mCRC, exploratory analyses also found that FOLFOXai predicted a treatment benefit from oxaliplatin-containing regimens in patients ...
- 1
- 2
- Next page »
